Symbols

GHRS

GH Research·NASDAQ

--(--)

GHRS Profile

Gh Research Plc

A clinical stage biopharmaceutical company that develops novel therpies for the management of mental diseases

Industry

Pharmaceutical

Established Date

03/29/2021

Listing Date

06/25/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ghres.com

Security Type

Common stock

Office address

Joshua Dawson House, Dawson Street, Dublin 2, D02 RY95, Ireland

Business

Introduction

GH Research PLC was incorporated under the laws of Ireland on 29 March 2021. The company is a clinical-stage biopharmaceutical company dedicated to transforming patients' lives by developing a treatment that transforms the practice of depression. The company's initial focus is on the development of new and proprietary mebufostin therapies for the treatment of patients with treatment-resistant depression (TRD). Their product portfolio currently includes GH001, a proprietary inhalable mebufostin product candidate, and GH002, a proprietary intravenous mebufostin product candidate.